Pepticom Ltd is developing an artificial intelligence (AI) platform for peptide drug discovery. The technology is based on research carried out at Hebrew University and later extensively developed by Pepticom. The platform uses the structure of the target protein to design innovative peptides at atomic resolution. It is capable of designing several types of peptides, including linear, helical, cyclic, and D-amino acid peptides. Pepticom is engaged in discovery projects with ADAMA, a large agricultural company, and the Eli Lilly Open Innovation program, in which active peptides were generated. Pepticom has two active EUREKA (prestigious European RandD initiative) projects that generated active peptides in animal models for Alzheimers disease and vaccine adjuvants. Using its technology, Pepticom has discovered drug candidates for diabetes, immunotherapy, and Alzheimers disease.